Sangamo Biosciences, Inc. (NASDAQ:SGMO) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 5, 2016
Boasting a price of $4.84, Sangamo Biosciences, Inc. (NASDAQ:SGMO) traded 0.42% higher on the day. With the last stock price close down -16.65% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Sangamo Biosciences, Inc. has recorded a 50-day average of $4.54 and a two hundred day average of $5.71. Volume of trade was down over the average, with 651,586 shares of SGMO changing hands under the typical 916,702
Zacks Investment Research has downgraded Sangamo Biosciences, Inc. (NASDAQ:SGMO) to Sell in a statement released on 10/05/2016.
With a total market value of $0, Sangamo Biosciences, Inc. has with a one year low of $4.08 and a one year high of $9.91 .
Brief Synopsis About Sangamo Biosciences, Inc. (NASDAQ:SGMO)
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics. Its ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It has preclinical programs in hemophilia A and Lysergic acid diethylamide and research stage programs in monogenic diseases, including certain central nervous system disorders and cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.